Carregando...
Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis
BACKGROUND: Tofacitinib, an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA), provides patients with an alternative to subcutaneously or intravenously administered biologic disease-modifying antirheumatic drugs (DMARDs). Little is known about patient preference for...
Na minha lista:
| Publicado no: | Am Health Drug Benefits |
|---|---|
| Principais autores: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Engage Healthcare Communications, LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4856233/ https://ncbi.nlm.nih.gov/pubmed/27182427 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|